Recordati signs new Ionis licensing deal, shares trade steadily in Milan
25.06.2026 - 19:07:48 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 19:07.
Recordati (IT0003828271) has signed a fresh licensing agreement with Ionis Pharmaceuticals for the experimental RNA-based drug zilganersen, adding a new rare disease asset to its neurology pipeline as reported by Alliance News and MarketScreener. The agreement covers exclusive development and commercialization rights outside the US, with the stock trading on Borsa Italiana in Milan.
Details of the Ionis licensing deal
According to an Alliance News dispatch carried by MarketScreener on Thursday, Recordati has entered into a licensing agreement with Ionis for zilganersen, an investigational therapy targeting Alexander disease, a severe and ultra-rare neurodegenerative disorder often caused by mutations in the GFAP gene. The deal grants Recordati exclusive rights to develop and commercialize the drug in all territories outside the United States, while Ionis retains the US market.
The report notes that zilganersen is an RNA-based therapy designed to reduce the production of abnormal GFAP protein, seeking to address the underlying biology of Alexander disease rather than just the symptoms. Alexander disease is typically characterized by progressive neurological decline, macrocephaly and white matter abnormalities, and currently has no approved disease-modifying treatments, which positions the asset squarely in the rare disease space consistent with Recordati’s specialty focus.
What Reuters and analysts highlight
Recordati’s move fits a broader pattern of mid-cap European pharma companies deepening ties with US biotech innovators to access specialized RNA and gene therapies, a trend covered in recent Reuters sector commentary on cross-border licensing and co-development deals. In this case, the ex-US structure allows Ionis to concentrate on the US market while leveraging Recordati’s established commercial footprint in Europe and selected international regions.
MarketScreener’s equity snapshot shows Recordati shares last closing at 51.55 euros, with an average analyst target price of 58.89 euros, indicating upside potential of roughly 14 percent from the latest close based on compiled broker estimates. The same data set cites a market capitalization of around 11.9 billion euros, underlining Recordati’s status as a sizeable specialty pharma player within the Italian equity universe rather than a small-cap niche stock.
All news and analysis on the Recordati shares
Further background, price data and earlier reports on Recordati can be found in the dedicated topic section and via the company’s Investor Relations page.
The product behind the stock
Recordati generates most of its revenue from specialty and primary care medicines in areas such as cardiology, urology and rare diseases, with its long-established hypertension drug portfolio providing a steady cash base. In recent years the company has expanded in rare metabolic and neurological disorders, including products acquired from Novartis for pituitary and endocrine indications, and the new zilganersen license reinforces that rare disease strategy.
Where the stock trades today
The Recordati shares (IT0003828271) trade on Borsa Italiana in Milan; the last verified close on MarketScreener was 51.55 euros as of 2026-06-25, 17:30.
Recordati at a glance
- Company: Recordati S.p.A.
- ISIN: IT0003828271
- WKN: 757395
- Ticker: RCD
- Trading venue: Borsa Italiana (Milan)
- Price (as of 2026-06-25, 17:30): 51.55 euros
- Market cap: 11.91 billion euros (as of 2026-06-25)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: FTSE MIB
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to trade any security. All data are based on sources believed to be reliable but cannot be guaranteed.
